Carlos Moreno-Cinos

Carlos Moreno-Cinos

Auto-generated profile, based on publicly available information

Carlos Moreno-Cinos

Laboratory of Medicinal Chemistry, University of Antwerp, Universiteitsplein 1, B-2610 Antwerp, Belgium

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CMCarlos Moreno-Cinos
Carlos Moreno-Cinos
KGKenneth Goossens
Kenneth Goossens
ISIrene G. Salado
Irene G. Salado
PVPieter Van Der Veken
Pieter Van Der Veken
HWHans De Winter
Hans De Winter
KAKoen Augustyns
Koen Augustyns
The caseinolytic protease proteolytic subunit (ClpP) is a serine protease playing an important role in proteostasis of eukaryotic organelles and prokaryotic cells. Alteration of ClpP function has been proved to affect the virulence and infectivity of a number of pathogens. Increased bacterial resistance to antibiotics has become a global problem and new classes of antibiotics with novel mechanisms of action are needed. In this regard, ClpP has emerged as an attractive and potentially viable option to tackle pathogen fitness without suffering cross-resistance to established antibiotic classes and, when not an essential target, without causing an evolutionary selection pressure. This opens a greater window of opportunity for the host immune system to clear the infection by itself or by co-administration with commonly prescribed antibiotics. A comprehensive overview of the function, regulation and structure of ClpP across the different organisms is given. Discussion about mechanism of action of this protease in bacterial pathogenesis and human diseases are outlined, focusing on the compounds developed in order to target the activation or inhibition of ClpP.

20 December 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CMCarlos Moreno-Cinos
Carlos Moreno-Cinos
ESElisa Sassetti
Elisa Sassetti
ISIrene G. Salado
Irene G. Salado
GWGesa Witt
Gesa Witt
SBSiham Benramdane
Siham Benramdane
KAKoen Augustyns
Koen Augustyns

14 October 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CJCedric Joossen
Cedric Joossen
ABAdrienn Baán
Adrienn Baán
CMCarlos Moreno-Cinos
Carlos Moreno-Cinos
JJJurgen Joossens
Jurgen Joossens
NCNathalie Cools
Nathalie Cools
PCPaul Cos
Paul Cos
Dry eye syndrome (DES), a multifactorial disorder which leads to ocular discomfort, visual disturbance and tear film instability, has a rising prevalence and limited treatment options. In this study, a newly developed trypsin-like serine protease inhibitor (UAMC-00050) in a tear drop formulation was evaluated to treat ocular inflammation. A surgical animal model of dry eye was employed to investigate the potential of UAMC-00050 on dry eye pathology. Animals treated with UAMC-00050 displayed a significant reduction in ocular surface damage after evaluation with sodium fluorescein, compared to untreated, vehicle treated and cyclosporine-treated animals. The concentrations of IL-1α and TNF-α were also significantly reduced in tear fluid from UAMC-00050-treated rats. Additionally, inflammatory cell infiltration in the palpebral conjunctiva (CD3 and CD45), was substantially reduced. An accumulation of pro-MMP-9 and a decrease in active MMP-9 were found in tear fluid from animals treated with UAMC-00050, suggesting that trypsin-like serine proteases play a role in activating MMP-9 in ocular inflammation in this animal model. Comparative qRT-PCR analyses on ocular tissue indicated the upregulation of tryptase, urokinase plasminogen activator receptor (uPAR) and protease-activated receptor 2 (PAR2). The developed UAMC-00050 formulation was stable up to 6 months at room temperature in the absence of light, non-irritating and sterile with compatible pH and osmolarity. These results provide a proof-of-concept for the in vivo modifying potential of UAMC-00050 on dry eye pathology and suggest a central role of trypsin-like serine proteases and PAR2 in dry eye derived ocular inflammation.

20 March 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ISIrene G. Salado
Irene G. Salado
ASAbhimanyu K. Singh
Abhimanyu K. Singh
CMCarlos Moreno-Cinos
Carlos Moreno-Cinos
GSGuna Sakaine
Guna Sakaine
MSMarco Siderius
Marco Siderius
KAKoen Augustyns
Koen Augustyns